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A vaccine for Human cytomegalovirus (HCMV) remains a high priority as complications 
following infection are observed in immunocompromised individuals and in congenitally 
infected neonates. Numerous preclinical and clinical studies have investigated vaccine 
strategies ranging from live attenuated preparations, nucleic acid-based approaches and 
recombinant delivery systems to subunit vaccines. These have defined the importance of 
both cell-mediated and humoral immunity to viral gB in the control of HCMV infection. This 
review will cover clinical trials investigating vaccine approaches that have incorporated gB 
and discuss the future perspectives of the recombinant gB subunit vaccine for HCMV.
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Background
Human cytomegalovirus (HCMV) is a ubiquitous pathogen, known to infect all human populations 
worldwide [1]. It is an enveloped dsDNA virus that is the largest member of the Herpesviridae family 
that also includes important pathogens, such as HSV-1 and HSV-2, EBV and varicella zoster virus 
(VZV), all of which are widespread in human populations [2]. The HCMV genome is approximately 
230 kbp encoding 200–250 open reading frames, many of which facilitate immune evasion [3]. A 
recent study of the HCMV genome and translation products has suggested that it may be even more 
complex than anticipated with regulation of alternate transcripts allowing for numerous polypeptides 
to be expressed [4]. Transmission of HCMV predominantly occurs via body fluids, such as saliva, 
blood, urine and breast milk, leading to contact of the mucosal surfaces, primarily infecting epithe-
lial and endothelial cells, followed by dissemination to numerous organs and tissues [5]. HCMV is, 
therefore, able to infect a wide range of cells including endothelial cells, epithelial cells, fibroblasts, 
smooth muscle cells, leukocytes and dendritic cells [5,6]. Similarly to other Herpesviridae family mem-
bers, HCMV is capable of both lytic and latent infections [7], but primary infection and reactivation 
from latency are often asymptomatic in immunocompetent individuals [8]. HCMV infection and 
reactivation in both solid organ and hematopoietic stem cell transplant recipients, and fetal expo-
sure in utero poses a major threat. Immunocompromised individuals, including AIDS patients [9,10] 
and transplant patients [11,12], are at increased risk of both reactivation or reinfection, and primary 
HCMV infection has serious consequences for the developing fetus in pregnant women [8]. It is 
estimated that HCMV congenital infection occurs in 0.5–2% of all annual pregnancies [13], and 
approximately 10% of infants with congenital HCMV infection present with clinical manifestations 
at birth, such as hearing loss and neurological developmental defects [14]. Additionally, late-onset 
hearing disorders can occur with both symptomatic and asymptomatic congenital infection, which 
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outlines the importance of monitoring this pop-
ulation [15]. Treatments for HCMV in transplant 
recipients include the use of antiviral drugs [16], 
although viral resistance and toxicity restricts 
their use, and hyper immune globulins [17], 
which may also be effective in treating con-
genital infections [18]. Based on the widespread 
prevalence of HCMV, limited treatment options 
and the potential for significant morbidity, an 
effective vaccine preventing congenital infection 
and infection of the immunocompromised has 
been characterized as a level 1 priority by the 
Institute of Medicine [14].
HCMV & gB structure
The HCMV envelope consists of several viral 
glycoproteins, including gB, heterodimer 
gH/gL and the gM/gN complex [19] that play 
critical roles in viral entry and envelope fusion 
to cells [20]. These glycoproteins are also tar-
gets of the immune response to HCMV, elicit-
ing neutralizing antibodies and cell-mediated 
immune responses, which suggests that they 
may serve as vaccine antigens. gB is probably 
the most well-studied viral glycoprotein and is 
highly conserved throughout the herpes virus 
family [21]. Together with gH/gL, gB mediates 
virus entry through membrane fusion and is 
known as the core fusion machinery common 
to all herpes viruses [22]. Studies have shown 
that gH/gL along with gB plays an indispen-
sable role in HCMV entry into fibroblasts 
and syncytium formation [23,24]. However, 
HCMV entry into other cell types, namely, 
epithelial cells and endothelial cells involves 
a complex of glycoproteins including gH, gL, 
UL128, UL130 and UL130A referred to as the 
gH/gL–pentamer complex (gH/gL–PC) [20,25]. 
In addition, gH/gL–PC is a prominent target 
for neutralizing antibodies that prevent infection 
of epithelial cells by HCMV [26–28]. Thus, the 
evidence points to the importance of both gB 
and gH/gL–PC for entry of HCMV and as key 
targets for antibodies.
The full-length gB polypeptide of 906 
amino acids is cleaved by the human protease 
furin [29] into two disulfide-bonded subunits 
known as gp58 and gp116, and is expressed in 
the HCMV envelope via a hydrophobic trans-
membrane domain (Figure 1) [30]. The structure 
of the HCMV gB ectodomain has been recently 
solved independently by two groups [31,32] and 
is thought to adopt a post-fusion trimeric con-
figuration in a similar fashion to that of HSV-1 
and EBV gB [21,33–34]. However, the HCMV gB 
structure displays a unique domain arrangement.
The recombinant gB used for structural stud-
ies and adopted as a subunit vaccine was first 
described in 1996 by Norais [35]. This synthe-
sized component contains the majority of the 
extracellular domain with the furin cleavage site 
mutated and the entire intracellular domain of 
Towne strain gB fused together with the inter-
vening transmembrane domain deleted to facili-
tate secretion (Figure 1). The recombinant gene 
was expressed in Chinese hamster ovary cell 
cultures and secreted as a protein of 807 amino 
acids containing 19 putative N-linked glycosyla-
tion sites. The structural studies required a trun-
cated version of recombinant gB known as the 
ectodomain where the N-terminal 78 residues, 
membrane proximal, transmembrane and cyto-
plasmic domains were removed to facilitate crys-
tallization. Despite the lack of these regions, it 
is known to adopt the post fusion conformation 
spontaneously and provides information regard-
ing antibody recognition, which has implica-
tions for vaccine design. In fact, these structures 
reflect the influence of gB glycosylation on anti-
body neutralization [31] and the interaction of a 
monoclonal antibody with a novel neutralizing 
epitope [32]. These recent discoveries are assisting 
with potential future modifications to gB that 
will improve its utility as a subunit vaccine.
Immune response to HCMV gB
As mentioned above, HCMV is able to infect 
a wide range of cells, such as endothelial cells, 
epithelial cells, fibroblasts, smooth muscle cells, 
leukocytes and dendritic cells [5,6], and this 
can influence the immune response generated. 
HCMV induces innate and adaptive immune 
responses that effectively resolve primary infec-
tion, however, it can still establish latency [36]. 
To complicate matters, HCMV is remarkable, 
in that it encodes numerous immune evasion 
molecules that target both innate and adaptive 
immune response mechanisms [36]. The innate 
immune response is triggered by detection and 
recognition of HCMV gB and gH through Toll-
like receptor 2 (TLR2) pathways [37], which 
leads to the initiation of the characteristic anti-
viral response inducing the production of type I 
interferons (IFN) and downstream expression of 
IFN-stimulated genes [38]. NK cells are thought 
to play an important role in innate control of 
HCMV infection as rare patients with NK cell 
deficiencies have increased severity of HCMV 
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Figure 1. The full-length Human cytomegalovirus gB polypeptide and important domains (upper 
part). The extracellular domain consists of amino acids 25–750 and contains several antigenic 
domains (AD-1, AD-2, AD-4, AD-5), the furin cleavage site and MP. A schematic of the synthesized 
recombinant gB that is used for gB subunit vaccine has a mutated furin cleavage site, and deleted TM 
domain is displayed below. 
HCMV: Human cytomegalovirus; MP: Membrane proximal domain; SS: Signal sequence; 
TM: Transmembrane domain.
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infections [39] and the virus itself targets NK 
cell activation via encoding numerous mecha-
nisms [36], although direct evidence is limited. 
Ultimately, the innate response plays an impor-
tant role in modulating the adaptive arm of the 
response as it is the first step in recognition of 
the pathogen [40].
T cells and antibody-mediated immune 
responses help to protect against HCMV infec-
tion and disease. Neutralizing antibodies alone 
are not capable of controlling HCMV infection 
but do have the ability to protect against HCMV-
associated diseases [41,42]. T-cell-mediated immu-
nity is the hallmark response when fighting 
virus infections and human T-cell responses to 
numerous HCMV glycoproteins have been iden-
tified in seropositive individuals [43,44] with gB 
being a frequently found viral antigen for CD4+ 
cells [45]. gB-specific cytotoxic CD8+ T cells and 
gB-specific effector CD4+ T cells have been iden-
tified in HCMV-seropositive individuals [46], 
and CD4+ cytotoxic cells are capable of recog-
nizing and destroying HCMV-infected cells [47]. 
T cells may, therefore, be critical for prevent-
ing dissemination of HCMV to other organs 
following initial infection of epithelial cells.
Antibodies to HCMV gB in human sera have 
been demonstrated to numerous functional 
domains of gB and are thought to play a role 
in limiting viral spread [48]. Neutralizing anti-
body epitopes of HCMV gB have been very well 
characterized, and there are known to be five 
antigenic domains (AD), AD-1 to AD-5. Four of 
these domains have been mapped (AD-1, AD-2, 
AD-4 and AD-5) to elicit human neutralizing 
antibodies [49]. AD-1 and AD-2 are the most 
well-characterized epitopes. AD-1 is a conforma-
tional epitope found on the C-terminal region 
of the gB polypeptide sequence at amino acids 
552–635 (Figure 1), but is found at the tip of the 
gB spike in the folded structure [31]. AD-1 elicits 
a strong IgG response in all infected individu-
als, however, not all AD-1 binding antibodies 
have virus neutralizing capabilities [50]. AD-2 is 
a shorter linear epitope on the N-terminus of the 
gB polypeptide (amino acids 68–78) (Figure 1) 
and, although not present in the solved gB struc-
ture, it is likely to be adjacent to the AD-1 
epitope at the tip of the gB spike [51]. Antibodies 
generated to AD-2 are unique, in that they are 
potently neutralizing antibodies, but approxi-
mately only 50% of seropositive individuals gen-
erate antibodies to this site [52], which is thought 
to be due to proximity to the larger more immu-
nogenic AD-1 epitope in the gB structure, which 
results in antigenic competition during immune 
responses [51]. Furthermore, human B cells have 
been shown to perform limited VDJ  recombina-
tion events that are required for antibodies that 
target AD-2 [53], whereas there are numerous 
possibilities for generation of AD-1-specific anti-
bodies. Interestingly, antibodies to AD-2 have 
been demonstrated to block placental infection 
of HCMV [54] and may, therefore, be the most 
critical site for antibodies to target to reduce 
vertical transmission. The AD-4 and AD-5 
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regions have been identified and mapped much 
more recently by isolating human B cells with 
affinity for recombinant gB [49]. AD-4 is located 
in domain II of the gB structure [31], which is 
a discontinuous region covering amino acids 
121–132 and 344–438 (Figure 1) and is well tar-
geted by HCMV-infected individuals eliciting 
neutralizing antibodies [55]. AD-5 is located in 
domain I of the gB structure [31], which is a large 
region spanning amino acids 133–343 (Figure 1), 
and antibodies to this region are found in most 
cases of HCMV infection [49]. A smaller surface-
exposed region of AD-5 known as the YNND 
epitope is thought to be the exclusive target of 
neutralizing antibodies that bind AD-5 [56]. 
Thus, HCMV gB is a useful target for multiple 
aspects of the human immune response and has, 
therefore, been viewed as a promising candidate 
for development as an HCMV vaccine.
Human trials of gB-containing HCMV 
vaccines
Numerous live vaccines for HCMV have under-
gone clinical trials since the 1970s. Showing the 
best effects was live attenuated HCMV vaccine 
(Towne strain), which was reported to be immu-
nogenic and decreased the severity of HCMV-
associated disease in HCMV seronegative renal 
transplant patients receiving seropositive kidneys 
despite not preventing HCMV infection [57,58]. 
Importantly, it was noted that the vaccine did 
not undergo latency in these patients [59]. The 
advancement on this work looked at recombi-
nant canarypox (ALVAC) as a vector for express-
ing HCMV gB (ALVAC-gB) [60]. ALVAC-gB 
was safe but only weakly immunogenic in seron-
egative subjects [61]. However, when adminis-
tered prior to immunization with live Towne 
strain HCMV to seronegative adults, binding 
and neutralizing antibodies to gB were found 
to be induced sooner and titers were stronger 
and longer lived than those receiving live Towne 
strain alone [61]. It was, therefore, suggested that 
this approach of priming followed by live vac-
cination may help to boost a protective antibody 
response. A similar priming effect has been 
shown with an HCMV trivalent DNA vac-
cine (VCL-CT02) encoding sequences of pp65, 
IE2 and gB. Administration of VCL-CT02 
prior to live Towne strain resulted in the boost-
ing of memory HCMV-specif ic antibody 
responses to gB and pp65-specific CD8+ T-cell 
responses [62]. Further trials of a DNA vaccine 
encoding HCMV gB and pp65 were performed 
in hematopoietic stem cell transplant patients. 
Results showed that the vaccine was well toler-
ated and reduced the occurrence and recurrence 
of HCMV viremia [63]. A brief summary of these 
trials is shown in Table 1.
Human trials of subunit gB vaccine
Recombinant HCMV gB was first used in 
a Phase I trial in conjunction with adjuvant 
MF59 [64]. Here, a double-blind, randomized, 
placebo-controlled was performed with healthy 
adult HCMV-seronegative volunteers receiving 
intramuscular (im.) one of three doses (5, 30 
or 100 μg; ten subjects/group) and comparing 
with 100 μg of HCMV gB with alum (ten sub-
jects) or placebo (six subjects). Immunizations 
were given at enrolment, 1 and 6 months later. 
A fourth dose of vaccine was given 12 months 
after the first immunization to subjects who 
consented to participate in an extension with 
12 months of follow-up after the fourth immu-
nization. The vaccine was safe and generated gB-
specific neutralizing antibodies at levels greater 
than seropositive control subjects following three 
Table 1. Summary of various gB-containing Human cytomegalovirus vaccines that have undergone clinical trials.
Study (year) HCMV vaccine Patient group(s) Key findings Ref.
Sachs et al. (1984), Plotkin 
et al. (1985), Plotkin et al. 
(1991)
Live Towne strain Renal transplant recipients Decreased severity of HCMV disease in 
seronegative patients receiving seropositive 
transplants
[57–59]  
Gonczol et al (1995), Adler 
et al. (1999) 
ALVAC-gB prime and live 
Towne
Healthy 
HCMV-seronegative adults
Weakly immunogenic but in combination 
with live Towne induces strong and long-lived 
neutralizing antibody responses
[60,61]
Jacobson et al. (2009) Trivalent DNA 
(gB/pp65/IE1) prime and 
live Towne
Healthy 
HCMV-seronegative adults
Increased cell-mediated immune responses 
and gB-specific antibody responses
[62]
Kharfan-Dabaja et al. 
(2012)
Bivalent DNA (gB/pp65) Hemopoietic stem cell 
transplant recipients
Reduced reactivation of HCMV viremia [63]
HCMV: Human cytomegalovirus.
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injections and even more so in the group receiv-
ing a fourth dose. The two lower doses of gB 
were found to be the most effective and MF59 
adjuvant induced stronger antibody responses 
than alum.
A parallel Phase I trial of HCMV gB adju-
vanted with MF59 was performed to evaluate 
safety and immunogenicity of low doses of 5 and 
30 μg in 95 HCMV-seronegative individuals [65]. 
Each dose was administered im. in one of three 
immunization schedules: 0, 1 and 2 months; 0, 
1 and 4 months; or 0, 1 and 6 months. Despite 
the significantly higher incidences of pain, 
warmth and myalgia at the injection site of the 
30-μg dose vaccine, overall the gB vaccine was 
well tolerated at both doses. Biochemical analy-
sis of the blood showed no significant changes 
in complete blood counts or liver/renal function. 
Interestingly, there was no significant difference 
in anti-gB antibody titers between the 5- and 
30-μg dose groups after the final immunization. 
However, 6 months post final immunization, 
there was a significantly higher antibody titer in 
the 0-, 1- and 6-month schedule in comparison 
with the others, emphasizing the importance of 
spacing out the doses to allow for a maximal long-
lived immune response. However, neutralizing 
antibody titers, although significantly higher in 
the 0-, 1- and 6-month group at 2 weeks post-
third immunization, was lost after 12 months. 
Thus, a result that was common to both of these 
Phase I subunit gB vaccine trials was that the 
antibody levels generated were not long lasting 
– an issue that remains unresolved but that may 
point to a requirement for continued antigenic 
stimulation of the immune response as is seen 
with natural HCMV infection.
A Phase I clinical trial of gB/MF59 was per-
formed in healthy young children (age range: 
12–35 months) to further evaluate safety and 
immunogenicity [66]. Fifteen children received a 
20-μg dose of gB/MF59 im. at 0, 1 and 6 months 
and adverse reactions were monitored along with 
gB-specific antibodies and HCMV neutralizing 
antibodies. It was concluded that the vaccine 
was well tolerated and highly immunogenic, 
with gB-specific and neutralizing antibodies 
reaching higher levels than seen in naturally 
infected adults and in adults given the gB/MF59 
vaccine.
Further progress has been made with the 
MF59 adjuvanted gB subunit vaccine. Phase II 
trials have been performed where it was admin-
istered to women of child-bearing age [67]. 
This study published in 2009 was a placebo- 
controlled, randomized, double-blind trial, 
where gB/MF59 vaccine (n = 234) or placebo 
(n = 230) were given at 0, 1 and 6 months to 
HCMV-seronegative women within 1 year after 
having given birth. The primary end point was 
the time until the detection of HCMV infec-
tion as determined by the presence of antibody 
to HCMV proteins other than gB. After 1 year 
of follow-up, there were 18 confirmed HCMV 
infections in the vaccine group compared with 
31 in the placebo group. Vaccine efficacy was 
calculated at 50% on the basis of infection rates 
per 100 person years. Just one congenital infec-
tion among infants of the subjects occurred 
in the vaccine group, whereas three infections 
occurred in the placebo group. While these 
results were encouraging, vaccine efficacy was 
relatively low and pointed to limited role of 
neutralizing antibody to gB alone as a useful 
correlate of protection.
gB/MF59 has also been administered to 
transplant patients [68]. Here a randomized, pla-
cebo-controlled Phase II trial was performed in 
adults awaiting kidney or liver transplantation. 
Both HCMV-seronegative and -seropositive 
patients were randomly assigned to receive either 
gB/MF59 vaccine or placebo, each given at base-
line, 1 month and 6 months later. End points 
were receipt of a transplant, HCMV viremia, 
immunogenicity and safety. Levels of gB-specific 
antibody were increased in both seronegative 
and seropositive patients in vaccine recipients as 
compared with placebo. The patients that devel-
oped viremia after transplantation displayed a 
shorter duration that correlated with higher lev-
els of gB-specific antibodies. In the seronegative 
patients receiving a transplant from a seroposi-
tive donor, the vaccine reduced the length of 
viremia and the amount of time undergoing 
ganciclovir treatment. These results are signifi-
cant since it is known that transplant-associated 
immune suppression via reduced cell-mediated 
immunity leads to HCMV disease, however, 
vaccine induction of gB-specific antibodies can, 
therefore, assist and again point to being a useful 
correlate of protection.
The most recent study of gB/MF59 was 
conducted in healthy seronegative adolescent 
girls [69]. This Phase II study was designed to 
determine safety and efficacy with an end point 
based on evidence of HCMV infection. Subjects 
were dosed with gB/MF59 or placebo at 0, 1 and 
6 months. The vaccine was safe, generated gB 
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antibody in all vaccine recipients, and efficacy 
was determined to be 43%, which is lower 
than conventional levels of significance but in 
line with prior investigations with the same 
formulation [67].
Thus three independent Phase II trials of 
gB/MF59 have indicated that antibody to gB 
is a possible correlate of protection for primary 
HCMV infection. Studies have yet to estab-
lish the role of gB vaccination (and, therefore, 
antibody protection) in HCMV reactivation. 
However, one clinical study has highlighted 
that gB vaccination can generate a limited cell-
mediated immune response and is suggestive 
of an important role of CD4+ T cells in verti-
cal HCMV transmission and potentially rein-
fection [70]. Interestingly, gB/MF59 boosted 
both the antibody-mediated and CD4+ T-cells 
responses to gB in chronically HCMV-infected 
women. In particular, these CD4+ T cells were 
found to release IFN-γ, indicating a type-I 
response that is known to activate CD8+ T cells. 
In addition, the CD4+ T cells had increased 
expression of the CD40 ligand (CD40L), a 
ligand that is a marker of recently activated 
T cells and also associated with T-cell-dependent 
antibody responses. All boosted responses were 
directly attributed to the gB vaccine as no boost-
ing of responses to alternate HCMV proteins 
was observed [70]. Taken together, these find-
ings demonstrate that gB/MF59 induces cell-
mediated immunity that helps boost pre-existing 
cell-mediated and antibody responses to gB. The 
application of gB/MF59, therefore, warrants fur-
ther trial in HCMV-seropositive recipients with 
reactivation as the primary end point. A sum-
mary of the gB/MF59 trials outlined above is 
shown in Table 2.
The future of HCMV gB subunit vaccine
Several clinical studies have outlined the impor-
tance of both cell-mediated and humoral immu-
nity to gB in the control HCMV infection of 
both healthy individuals and also immuno-
compromised hosts where the disease burden 
is most significant [41–43,45–47]. Maternal IgG 
is also critical in protection of the unborn 
fetus from congenital HCMV infection [18,41]. 
Numerous vaccine approaches such as live virus 
strains and recombinant delivery vectors have 
been attempted since the 1970s (Table 1), and 
while many have displayed reasonable efficacy, 
a licensed HCMV vaccine that will protect the 
most at-risk groups still does not exist. The 
difficultly appears to arise through the complex 
immunity required for complete protection to 
HCMV and the lack of knowledge of exactly 
what constitutes immune correlates of protec-
tion [36]. Even the immunity acquired via natural 
HCMV exposure, which is sufficient for initial 
viral clearance and recovery from infection in 
most individuals, does not fully protect from the 
high probability of reactivation due to the latent 
life cycle of the virus and the numerous immune 
evasion strategies the virus can adopt [36]. It has, 
therefore, been difficult to replicate long-lived 
protective immunity to HCMV with the vaccine 
approaches employed to date.
A new generation of vaccine candidates has 
been explored, one of which is the subunit gB 
immunogen that is adjuvanted with MF59. This 
approach has offered hope by displaying clini-
cal efficacy through the generation of relatively 
robust neutralizing antibody titers and possibly 
through the induction of cell-mediated immu-
nity [67,68]. Importantly, the gB/MF59 is safe in 
children [66] and adults [64,65], as well as being 
immunogenic, but is clearly not the ideal HCMV 
vaccine yet – improvements are required.
It still needs to be determined if gB/MF59 
induces the full spectrum of gB neutralizing 
antibodies observed following natural expo-
sure. Neutralizing antibodies are induced with 
gB/MF59 in seronegative recipients [64–68] and 
boosted in seropositive recipients [68]. While it 
is likely that gB/MF59 induces antibodies to the 
major neutralizing epitopes AD-1, AD-2, AD-4 
and AD-5, no study has yet evaluated this com-
pletely. Responses to AD-2 following vaccina-
tion with live Towne strain with and without 
ALVAC-gB priming or gB/MF59 displayed 
similarities to natural exposure, that is, only a 
fraction of recipients produced AD-2-specific 
antibodies [71]. This limited response to AD-2 is 
probably due to AD-1 antibodies out-competing 
the response to this epitope as described previ-
ously [51] and has suggested that modifications 
to recombinant gB or the vaccine regimen itself 
may improve responses to AD-2 and, there-
fore, improve vaccine efficacy [51,72]. Antibodies 
binding AD-1, AD-4 and AD-5 have not been 
investigated in gB/MF59 recipients. However, 
further studies mapping the neutralizing anti-
body responses to gB/MF59 will be forthcoming 
and will indicate improvements that could be 
made to the existing gB/MF59 strategy. They 
may even identify novel neutralizing epitopes 
that have not been found in prior studies.
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The limited longevity of the immune 
responses generated by gB/MF59 vaccina-
tion also needs addressing. Studies in seron-
egative recipients have indicated that protec-
tive responses are not long lived [65], and a 
similar loss of boosted responses in seropositive 
recipients has been noted [68]. This is observed 
despite three separate administrations of vac-
cine over a 6-month regimen and in one study 
a fourth dose after 12 months and suggests that 
there is a limited T-helper response generated 
to the vaccine. Perhaps it is worth investigat-
ing a protracted regimen over a longer period 
to improve longevity. Interestingly, toddlers 
that received gB/MF59 displayed higher 
titer antibody responses than adults [66], sug-
gesting that a longer vaccination regimen in 
these individuals and natural HCMV expo-
sure may promote long-lived immunity into 
adulthood. Alternatively, improved adjuvants 
could be applied. There are currently four 
adjuvants licensed for use in humans, oil-in-
water emulsions AS03 and MF59, alum and 
an alum monophosphoryl lipid A combination 
(AS04) [73]. These adjuvants may not provoke 
the desired immune responses in recipients and 
work is underway to develop tuneable adjuvant 
formulations [73].
Cellular immune responses to HCMV are 
critical for complete protective immunity to 
HCMV and these responses are clearly not 
optimally delivered by a recombinant subunit 
vaccine approach. Nevertheless, gB-specific 
CD4+ responses following gB/MF59 have been 
observed in seropositive recipients [70], but this 
has not been determined in seronegative recipi-
ents. It is likely that gB alone in the seronega-
tive recipients does not promote a broad enough 
cellular immune response. Therefore, it may be 
desirable to increase the valency of the subunit 
HCMV vaccine candidates to include other 
targets (gH/gL and gM/gN) in combination 
with gB. This approach would deliver more 
broad antibody coverage but may not deliver 
the required cellular responses adequately so 
a prime and boost regimen could be favored. 
Thus, another approach might be to increase 
vaccine valency by using gB in combination 
with dominant T-cell antigens, such as IE1 and 
pp65 [74–76]. A possible avenue for generation 
of suitable immunity might be to use DNA-
based vaccines, which encode key antigens that 
can prime both B and T cells prior to gB [77]. 
In Phase II trials, this priming approach in 
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combination with live boosting was shown to 
reduce HCMV viremia and also to increase 
the production of memory HCMV-specific 
antibodies [62,63]. To our knowledge, the DNA 
priming approach followed by gB/MF59 
boosting has not been attempted.
Overall, the development and relative success 
of the recently trialed gB/MF59 subunit vac-
cine is encouraging and offers a new outlook 
to what was previously known about immu-
nity to gB and, therefore, protection against 
HCMV. Nevertheless, potential improvements 
such as immunogen redesign to induce broader 
neutralizing antibody responses and regimen 
modifications to improve response longevity 
and cell-mediated responses may induce a more 
efficacious vaccine for the often serious conse-
quences attributed to HCMV infection. The 
possibility of a multivalent subunit immunogen 
approach that includes gB and other important 
HCMV targets to broaden protective immune 
responses should also be investigated. In this 
regard, the importance of the gH/gL–PC can-
not be underestimated and is coincidentally 
under development as a potential HCMV 
vaccine [78].
EXECUTivE SUMMARY
Background
 ●  Human cytomegalovirus (HCMV) is a ubiquitous human pathogen of the Herpesviridae family.
 ●  It is a large complex DNA virus transmitted by body fluids.
 ●  HCMV infects a wide range of cells and has both lytic and latent life cycles.
 ●  It is a critical pathogen for the immunocompromised, transplant recipients and congenitally infected babies.
 ●  There are few effective treatments and no licensed vaccine is available.
HCMV & gB structure
 ●  The HCMV envelope contains numerous glycoproteins that are conserved within the herpes virus family.
 ●  gB is the most-studied HCMV glycoprotein and is critical for viral entry.
 ●  The gB crystal structure has been recently solved.
 ●  Recombinant gB has been synthesized and used as a subunit vaccine.
Immune response to HCMV gB
 ●  HCMV induces innate and adaptive immune responses that can resolve primary infection.
 ●  Cytotoxic and helper T-cell responses to gB have been demonstrated.
 ●  Neutralizing antibody responses to four antigenic determinants (AD-1, AD-2, AD-4, AD-5) of gB have been extensively 
studied.
Human trials of gB-containing HCMV vaccines
 ●  Live attenuated vaccines have been tested and display varying efficacy.
 ●  Recombinant delivery systems of HCMV gB have been trialed in humans.
 ●  Trivalent DNA vaccines have also been trialed in humans.
 ●  Prime-boost regimens show the best efficacy.
Human trials of subunit gB vaccine
 ●  Recombinant gB adjuvanted with MF59 has undergone several clinical trials.
 ●  gB/MF59 is safe and immunogenic but displays limited efficacy in Phase II trials.
 ●  Antibody responses to gB appear to be a useful correlate of protection.
The future of HCMV gB subunit vaccine
 ●  Numerous vaccine approaches have been trialed but a licensed HCMV vaccine does not yet exist.
 ●  The gB subunit vaccine is promising but modifications and improvements to the immunogen, formulation and 
regimen are required to boost efficacy.
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Conclusion & future perspective
The use of gB as a subunit vaccine for HCMV 
has shown encouraging results but will more than 
likely not provide the immunity required for com-
plete protection. Modifications to the immunogen 
itself, additional immunogens in the formulation, 
improved adjuvants and alterations to the admin-
istration regimen are the key changes that could 
make improvements to the gB vaccine, ultimately 
making it successful in future clinical trials.
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